Vandana B. Patravale

Potential speakers for drug conferences-Vandana B. Patravale

Title: Smart lipid nanocarriers: Potential for intracellular targeting

Vandana B. Patravale

Institute of chemical technology, India


Vandana Patravale is Professor of Pharmaceutics at Department of Pharmaceutical Sciences and Technology of Institute of Chemical Technology, India. She has over 100 refereed publications, 8 granted patents, 24 patents in pipeline, 2 trademark registries with over 250 research presentations and 50 invited lectures at major national and international scientific meetings. She has published two books entitled, ‘Nanotechnology in drug delivery-A Perspective on transition from laboratory to market’ and ‘Pharmaceutical product development: insights into pharmaceutical processes, management and regulatory affairs’. She is recipient of prestigious Bill and Melinda Gates Foundation grant to develop the first ever eco-friendly nanovaccine for nasal immunization and was bestowed with esteemed awards like OPPI women scientist award 2015, Best Pharmaceutical Scientist award 2014, VASVIK award 2013, Veneto nanotech award 2013, APTI best teacher award 2012.


Intracellular delivery of anticancer drugs and therapeutic genes (DNA, siRNA, shRNA etc.) is a challenging task faced by pharmaceutical formulators necessitating the need for effective strategies which facilitate superior transfection and endosomal escaping ability. Taking this into consideration, we have designed and synthesized a novel amphiphilic, cationic heterolipid. This cationic heterolipid was employed in fabrication of smart nano carriers namely cationic self-microemulsifying drug delivery system (C-SMEDDS) for etoposide and monoguinoplex for gene therapy. C-SMEDDS (size <50 nm and zeta potential +32.6 mV) exhibited significant in vitro antiproliferative activity against B16F10 cell line. C-SMEDDS were observed to localize in cytoplasmic, perinuclear and nuclear space of cancer cells and mechanistic studies revealed clathrin mediated pathway, cytoskeletal reorganization and energy dependent uptake as the possible cellular entry mechanisms. The in vivo antitumor activity studies in preclinical melanoma tumor model presented superior tumor suppression ability at therapeutic and sub-therapeutic dose with 100% survival without any signs of hepatotoxicity and nephrotoxicity assuring high efficacy and safety. Monoguinoplex comprised heterolipid complex with p53 gene & GFP based plasmid. The complexation resulted in condensation of DNA bulk structure that offered protection to DNA from endonuclease enzymes and the same was confirmed using DNAase protection assay. The mammalian cells transfection assay proved superior transfection with monoguinoplex and was corroborated using confocal and flow cytometry assessment. Overall, the studies revealed not only a significant enhancement in intracellular uptake but also addressed biopharmaceutical issues related to non- site specific drug delivery and associated toxicity. Thus, the developed heterolipid based nanocarriers present a smart platform for intracellular release of cargo. 

Audience will learn:
•A thought process towards innovative formulation strategy development 
•Researchers will get an outline of in-depth study planning and execution from ideation to product realization

Key features:
•Next generation novel and efficacious approaches to treat cancer 
•Industrially feasible and scalable platform technology with multitude applications